Syndax Pharmaceuticals (SNDX)
(Real Time Quote from BATS)
$18.20 USD
-0.08 (-0.44%)
Updated Sep 25, 2024 11:42 AM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Income Statements
Fiscal Year end for Syndax Pharmaceuticals, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 140 | 2 | 2 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 140 | 2 | 2 |
Selling & Adminstrative & Depr. & Amort Expenses | 230 | 152 | 113 | 73 | 59 |
Income After Depreciation & Amortization | -230 | -152 | 26 | -71 | -58 |
Non-Operating Income | 21 | 6 | 1 | 1 | 1 |
Interest Expense | 0 | 3 | 2 | 2 | 0 |
Pretax Income | -209 | -149 | 25 | -73 | -56 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -209 | -149 | 25 | -73 | -56 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -209 | -149 | 25 | -73 | -56 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -245 | -155 | 27 | -71 | -58 |
Depreciation & Amortization (Cash Flow) | -15 | -3 | 1 | 0 | 0 |
Income After Depreciation & Amortization | -230 | -152 | 26 | -71 | -58 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 70.37 | 60.76 | 52.07 | 41.31 | 30.49 |
Diluted EPS Before Non-Recurring Items | -2.98 | -2.46 | 0.48 | -1.87 | -1.84 |
Diluted Net EPS (GAAP) | -2.98 | -2.46 | 0.46 | -1.87 | -1.84 |
Fiscal Year end for Syndax Pharmaceuticals, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 3.50 | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 3.50 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 77.72 | 79.51 | 77.91 | 56.36 | 49.67 |
Income After SG&A, R&D, and Dept/Amort Expenses | -74.22 | -79.51 | -77.91 | -56.36 | -49.67 |
Non-Operating Income | 6.20 | 7.17 | 5.50 | 5.28 | 5.10 |
Interest Expense | 0.05 | 0.06 | 0.06 | 0.07 | 0.04 |
Pretax Income | -68.06 | -72.40 | -72.47 | -51.15 | -44.62 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -68.06 | -72.40 | -72.47 | -51.15 | -44.62 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -68.06 | -72.40 | -72.47 | -51.15 | -44.62 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 85.28 | 85.21 | 72.52 | 69.86 | 69.64 |
Diluted EPS Before Non-Recurring Items | -0.80 | -0.85 | -1.00 | -0.73 | -0.64 |
Diluted Net EPS (GAAP) | -0.80 | -0.85 | -1.02 | -0.73 | -0.64 |